Omada Health (NASDAQ:OMDA) Coverage Initiated by Analysts at Citizens Jmp

Key Points

• Citizens Jmp initiated coverage with a "market outperform" rating and an $18 price target (about 48.5% upside), while the analyst consensus per MarketBeat is a "Moderate Buy" with an average price target of $21.64 (10 Buys, 2 Holds, 1 Sell).
• Recent results: Omada reported Q results with EPS of $0.08 (beating the -$0.04 estimate) and revenue of $75.85M; the stock trades around $12.12 with a market cap of ~$714M and a 52-week range of $10.28–$28.40.
• Insider selling: CEO Sean Duffy sold 4,063 shares and President Wei‑Li Shao sold 2,829 shares, and insiders disposed of 8,776 shares (~$120,483) over the last quarter.

Citizens Jmp began coverage on shares of Omada Health (NASDAQ:OMDA - Get Free Report) in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage set a "market outperform" rating and a $18.00 price target on the stock. Citizens Jmp's price target would indicate a potential upside of 48.51% from the stock's previous close.

Several other equities analysts have also recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price target on shares of Omada Health in a report on Thursday, January 22nd. Barclays decreased their price target on Omada Health from $22.00 to $17.00 and set an "overweight" rating on the stock in a report on Tuesday, March 3rd. Evercore reiterated an "outperform" rating and issued a $15.00 price target on shares of Omada Health in a report on Wednesday, April 8th. Canaccord Genuity Group decreased their price target on Omada Health from $28.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, March 6th. Finally, Wells Fargo & Company initiated coverage on Omada Health in a report on Thursday, January 8th. They issued an "equal weight" rating and a $17.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $21.64.

Omada Health Stock Performance

Shares of OMDA stock opened at $12.12 on Tuesday. The stock's fifty day moving average is $12.68 and its 200-day moving average is $16.87. The stock has a market capitalization of $714.11 million and a PE ratio of -71.29. Omada Health has a 52 week low of $10.28 and a 52 week high of $28.40.

Omada Health (NASDAQ:OMDA - Get Free Report) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.12. The firm had revenue of $75.85 million during the quarter.

Insiders Place Their Bets

In other Omada Health news, CEO Sean P. Duffy sold 4,063 shares of the firm's stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $14.34, for a total transaction of $58,263.42. Following the transaction, the chief executive officer owned 117,598 shares in the company, valued at approximately $1,686,355.32. This trade represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Wei-Li Shao sold 2,829 shares of the firm's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $12.71, for a total value of $35,956.59. Following the transaction, the president owned 328,850 shares in the company, valued at approximately $4,179,683.50. This trade represents a 0.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 8,776 shares of company stock worth $120,483.

Hedge Funds Weigh In On Omada Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in Omada Health during the third quarter worth about $38,000. Raymond James Financial Inc. acquired a new stake in shares of Omada Health during the second quarter worth about $32,000. Bellevue Group AG raised its position in shares of Omada Health by 0.7% during the third quarter. Bellevue Group AG now owns 251,791 shares of the company's stock worth $5,567,000 after purchasing an additional 1,791 shares during the period. Quarry LP acquired a new stake in shares of Omada Health during the fourth quarter worth about $29,000. Finally, Barclays PLC raised its position in shares of Omada Health by 14.6% during the fourth quarter. Barclays PLC now owns 14,850 shares of the company's stock worth $234,000 after purchasing an additional 1,888 shares during the period.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.